Regen BioPharma, Inc. (RGBP)
USD 0.05
(-12.78%)
USD 0.05
(-12.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 923.51 Thousand USD | 60.58% |
| 2022 | 575.12 Thousand USD | 54.62% |
| 2021 | 371.96 Thousand USD | 16.49% |
| 2020 | 319.31 Thousand USD | -63.16% |
| 2019 | 866.78 Thousand USD | -43.19% |
| 2018 | 1.52 Million USD | -41.78% |
| 2017 | 2.62 Million USD | -14.27% |
| 2016 | 3.05 Million USD | 40.79% |
| 2015 | 2.17 Million USD | 207.39% |
| 2014 | 706.35 Thousand USD | 120.85% |
| 2013 | 319.83 Thousand USD | -20.29% |
| 2012 | 401.25 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 181.84 Thousand USD | 53.52% |
| 2024 Q2 | 160.13 Thousand USD | -11.94% |
| 2024 Q3 | 167.03 Thousand USD | 4.31% |
| 2023 Q3 | 102.62 Thousand USD | -25.58% |
| 2023 Q1 | 522.93 Thousand USD | 232.77% |
| 2023 Q2 | 137.9 Thousand USD | -73.63% |
| 2023 FY | 923.5 Thousand USD | 60.58% |
| 2023 Q4 | 118.45 Thousand USD | 15.42% |
| 2022 Q3 | 117.62 Thousand USD | -12.78% |
| 2022 Q4 | 157.14 Thousand USD | 33.6% |
| 2022 FY | 575.12 Thousand USD | 54.62% |
| 2022 Q1 | 165.48 Thousand USD | -11.29% |
| 2022 Q2 | 134.86 Thousand USD | -18.51% |
| 2021 Q3 | 99.12 Thousand USD | 145.36% |
| 2021 Q2 | 40.39 Thousand USD | -12.0% |
| 2021 FY | 371.96 Thousand USD | 16.49% |
| 2021 Q1 | 45.9 Thousand USD | -1.57% |
| 2021 Q4 | 186.53 Thousand USD | 88.19% |
| 2020 Q4 | 46.63 Thousand USD | 6.57% |
| 2020 FY | 319.31 Thousand USD | -63.16% |
| 2020 Q3 | 43.76 Thousand USD | -34.45% |
| 2020 Q2 | 66.75 Thousand USD | -58.83% |
| 2020 Q1 | 162.16 Thousand USD | -25.33% |
| 2019 Q3 | 165.14 Thousand USD | -36.04% |
| 2019 Q4 | 217.16 Thousand USD | 31.5% |
| 2019 FY | 866.78 Thousand USD | -43.19% |
| 2019 Q1 | 226.25 Thousand USD | -13.44% |
| 2019 Q2 | 258.21 Thousand USD | 14.12% |
| 2018 Q3 | 226.37 Thousand USD | -49.52% |
| 2018 Q4 | 261.4 Thousand USD | 15.47% |
| 2018 FY | 1.52 Million USD | -41.78% |
| 2018 Q1 | 879.58 Thousand USD | 28.39% |
| 2018 Q2 | 448.42 Thousand USD | -49.02% |
| 2017 Q3 | 663.05 Thousand USD | -10.3% |
| 2017 Q4 | 685.09 Thousand USD | 3.32% |
| 2017 FY | 2.62 Million USD | -14.27% |
| 2017 Q1 | 533.58 Thousand USD | -31.31% |
| 2017 Q2 | 739.15 Thousand USD | 38.53% |
| 2016 Q1 | 689.45 Thousand USD | -3.58% |
| 2016 Q2 | 719.87 Thousand USD | 4.41% |
| 2016 Q3 | 870.78 Thousand USD | 20.96% |
| 2016 FY | 3.05 Million USD | 40.79% |
| 2016 Q4 | 776.85 Thousand USD | -10.79% |
| 2015 Q2 | 621.41 Thousand USD | 191.19% |
| 2015 FY | 2.17 Million USD | 207.39% |
| 2015 Q1 | 213.4 Thousand USD | 10.8% |
| 2015 Q4 | 715.03 Thousand USD | 15.07% |
| 2015 Q3 | 621.41 Thousand USD | -0.0% |
| 2014 FY | 706.35 Thousand USD | 120.85% |
| 2014 Q1 | 185.83 Thousand USD | 124.81% |
| 2014 Q3 | 157.86 Thousand USD | -7.16% |
| 2014 Q4 | 192.6 Thousand USD | 22.01% |
| 2014 Q2 | 170.04 Thousand USD | -8.5% |
| 2013 Q1 | 91.83 Thousand USD | 0.0% |
| 2013 Q4 | 82.66 Thousand USD | 10.47% |
| 2013 Q2 | 70.5 Thousand USD | -23.23% |
| 2013 Q3 | 74.82 Thousand USD | 6.13% |
| 2013 FY | 319.83 Thousand USD | -20.29% |
| 2012 FY | 401.25 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 30.846% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 81.684% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.875% |
| Nascent Biotech, Inc. | 2.22 Million USD | 58.585% |
| Rebus Holdings, Inc. | 664 Thousand USD | -39.083% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.521% |
| Qrons Inc. | 643.67 Thousand USD | -43.474% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -137.061% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.392% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -122.276% |
| Skye Bioscience, Inc. | 13.54 Million USD | 93.183% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.936% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 81.222% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -252.854% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.921% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 68.332% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 38.511% |
| Mesoblast Limited | 5.9 Million USD | 84.353% |
| Marizyme, Inc. | 19.23 Million USD | 95.2% |
| Genus plc | 147.7 Million USD | 99.375% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 89.481% |
| Pharming Group N.V. | 225.49 Million USD | 99.59% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 54.922% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 31.161% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 88.925% |
| ContraFect Corporation | 56.88 Million USD | 98.377% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 79.052% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 37.548% |
| IMV Inc. | 37.7 Million USD | 97.551% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 66.904% |
| MultiCell Technologies, Inc. | 567.42 USD | -162655.983% |
| ONE Bio Corp. | 6.44 Million USD | 85.668% |
| Accustem Sciences Inc. | 3.74 Million USD | 75.35% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.925% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -73.605% |
| Q BioMed Inc. | 3.43 Million USD | 73.127% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 96.263% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 64.852% |
| Biomind Labs Inc. | 994.18 Thousand USD | 7.109% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.07% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 47.518% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 86.253% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 50.465% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3794.04% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 94.232% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 49.675% |
| GB Sciences, Inc. | 1.42 Million USD | 34.987% |
| Alpha Cognition Inc. | 9.7 Million USD | 90.485% |
| HST Global, Inc. | 140.9 Thousand USD | -555.404% |
| CSL Limited | 3.44 Billion USD | 99.973% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 17.904% |
| Halberd Corporation | 74.84 Thousand USD | -1133.946% |
| Enzolytics Inc. | 2.17 Million USD | 57.628% |
| Agentix Corp. | 1.37 Million USD | 32.677% |
| Resverlogix Corp. | 12.71 Million USD | 92.735% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 74.703% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.94% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 11.541% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 61.599% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 41.526% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 72.878% |
| AVAX Technologies, Inc. | 7.31 Million USD | 87.367% |
| Zenith Capital Corp. | 8.94 Million USD | 89.673% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.888% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5201.131% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 62.387% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -438.462% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 51.923% |
| Kadimastem Ltd | 2.41 Million USD | 61.682% |
| Helix BioMedix, Inc. | 1.97 Million USD | 53.17% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 91.502% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.98% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -408.863% |
| LadRx Corporation | 3.81 Million USD | 75.772% |
| Cell Source, Inc. | 4.32 Million USD | 78.649% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 0.0% |
| NovAccess Global Inc. | 2.46 Million USD | 62.562% |
| Affymax, Inc. | 39.38 Million USD | 97.655% |
| Itoco Inc. | 919.14 Thousand USD | -0.475% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 78.211% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 17.47% |
| Mobile Lads Corp. | 554.54 Thousand USD | -66.534% |
| CytoDyn Inc. | 18.05 Million USD | 94.886% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3569.236% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -319.628% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 34.955% |
| SYBLEU INC | 160.87 Thousand USD | -474.051% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 49.155% |
| International Stem Cell Corporation | 5.27 Million USD | 82.479% |
| Bioxytran, Inc. | 3.82 Million USD | 75.825% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1654.322% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4439.694% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.454% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 42.923% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -25.505% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 70.315% |
| Neutra Corp. | 243.82 Thousand USD | -278.766% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 94.71% |
| PureTech Health plc | 144.59 Million USD | 99.361% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 95.493% |
| IXICO plc | 4.7 Million USD | 80.38% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 89.502% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.216% |
| CSL Limited | 3.89 Billion USD | 99.976% |
| Cellectis S.A. | 97.32 Million USD | 99.051% |